EPCAM and metabolic dysfunction-associated steatohepatitis: We demonstrate that the NASH liver is favorable to EpCAM+ CSC-mediated tumorigenesis in immunocompetent microenvironments, but not the normal liver or the nonprogressive bland steatosis.